Cell and Gene Therapy Supply Chain Software Market

Cell and Gene Therapy Supply Chain Software Market - Distribution by Process Component (Sample Collection and Processing Component, Manufacturing Component, Logistics Component, and Patient Identification and Treatment Follow-Up Component), Type of Software (EMS, LIMS, IMS, COP, QMS, LMS and PMS), Mode of Deployment (On-premise Deployment and Cloud-based Deployment), Scale of Operation (Clinical Scale and Commercial Scale), Type of End-User (Pharmaceutical Companies, Cell Therapy Labs, Hospitals / Medical Centers and Research Institutes / Biobanks) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World: Industry Trends and Global Forecasts

The cell and gene therapy supply chain software market is valued at USD 274 billion in 2024 growing at a CAGR of 15.2% during the forecast period 2024-2035.

Pioneering cell and gene therapies have catalyzed a paradigm shift in healthcare delivery, revolutionizing the development, production, and consumption of cutting-edge medicine. These groundbreaking therapeutics have empowered healthcare professionals to combat rare clinical conditions that once seemed insurmountable. Over the past few decades, more than 30 such transformative modalities have garnered regulatory approval, with recent triumphs including ELEVIDYS® (2023), Adstiladrin® (2022), Breyanzi® (2022), CARVYKTI® (2022), Abecma® (2021), Allocord™ (2019), LUXTURNA™ (2017), and Yescarta® (2017). Moreover, a report by Novotech heralded the anticipated approval of more than 12 novel cell and gene therapies by the end of 2023, underscoring lucrative prospects for stakeholders in this burgeoning domain. Notably, post-2018, over 40% of clinical trials addressing rare diseases involved the evaluation of innovative cell and gene therapy products. Based on the current pipeline and historical clinical success rates, projections indicate that the United States Food and Drug Administration could approve 10-20 advanced therapies annually until 2025. Consequently, the demand for innovative software solutions to streamline supply chain management is poised to surge, presenting growth opportunities for cell and gene therapy software providers.

Importantly, the commercial triumph of cell and gene therapy products hinges not only on their therapeutic efficacy but also on developers' ability to seamlessly navigate complex supply chain intricacies. The cell and gene therapy supply chain is inherently more intricate than conventional pharmaceutical supply chains due to the temperature sensitivity and uniqueness of these products. Consequently, therapy developers must grapple with an array of risks, including operational inefficiencies, capacity scheduling challenges, process delays leading to capital losses, and delivery/tracking-related issues. This intricate landscape has fueled the need for tailored software solutions that can seamlessly integrate with existing processes, empowering drug developers to oversee and manage every aspect of the cell and gene therapy supply chain at each juncture. Over time, numerous innovative software solutions have emerged, offering supply chain orchestration and needle-to-needle traceability capabilities. The market has witnessed a surge in partnerships aimed at advancing these software solutions. Furthermore, driven by the growing demand for cost-effective personalized medicinal products and the cost-saving potential of implementing such software solutions, the cell and gene therapy supply chain software market is poised for substantial growth.

Key Market Segments

Process Component

Sample Collection and Processing Component

Manufacturing Component

Logistics Component

Patient Identification and Treatment Follow-up Component

Type of Software

Enterprise Manufacturing System (EMS)

Laboratory Information Management System (LIMS)

Inventory Management System (IMS)

Cell Orchestration Platform (COP)

Quality Management System (QMS)

Logistics Management System (LMS)

Patient Management System (PMS)

Mode of Deployment

On-premises Deployment

Cloud-based Deployment

Type of End-User

Pharmaceutical Companies

Cell Therapy Labs

Hospitals / Medical Centers

Research Institutes / Biobanks

Type of End-User

Clinical Scale

Commercial Scale

Geographical Regions

North America

Europe

Asia-Pacific

Rest of the World

Research Coverage:

The report studies the cell and gene therapy supply chain software market based on process component, type of software, mode of deployment, type of end-user, scale of operation and key geographical regions.

The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.

The report forecasts the revenue of market segments with respect to four major regions

The report begins with a general overview of the cell and gene therapy supply chain, highlighting different types of software solutions, their key features, and applications. It also covers the advantages of supply chain software in this industry, challenges with conventional supply chains, and opportunities and future perspectives associated with supply chain management software.

It provides a detailed overview of the current market landscape for cell and gene therapy supply chain software solutions, based on parameters such as software type (cell orchestration platform, enterprise manufacturing system, inventory management system, laboratory information management system, logistics management system, patient management system, quality management system, and tracking and tracing system), key features (compatibility/integration, traceability, data analytics/visualization, scalability, user-friendliness, chain of identity/custody), application area, mode of deployment, scale of operation, regulatory guidelines followed, and end-user type. Additionally, it lists developers offering these solutions, analyzing them based on establishment year, company size, headquarters location, and active players.

The report offers an insightful competitiveness analysis of companies in this market, based on developer strength (experience, company size) and product portfolio strength (partnerships, application areas, features, end-users, deployment mode, operation scale, regulatory guidelines).

It includes elaborate profiles of key software providers, featuring company overviews, software portfolios, financial information, recent developments, and future outlooks.

The report provides an in-depth analysis of funding and investments in this domain since 2014, including seed funding, venture capital, debt financing, grants/awards, IPO proceeds, and subsequent offerings received by companies operating in this market.

It presents a detailed analysis of partnerships, including acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements, and others, inked between companies in this market since 2019.

The report offers an in-depth analysis of platform utilization agreements signed since 2019, providing information on different software types utilized by end-users in the cell and gene therapy supply chain.

It includes a qualitative assessment of current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers, regulators/payers) involved in the cell and gene therapy supply chain, highlighting the diverse needs and their impact on the supply chain and industry preparedness.

The report provides an in-depth analysis of factors impacting the growth of this market, including key drivers, potential restraints, emerging opportunities, and existing challenges.

It offers a detailed estimate of the current market size and future growth potential of the cell and gene therapy supply chain software market until 2035, based on likely adoption trends and reliable secondary and primary validations. The report features three forecast scenarios (conservative, base, optimistic) to account for future uncertainties.

The report includes detailed projections of the current and future market opportunity across various process components (sample collection/processing, manufacturing, logistics, patient identification/treatment follow-up), software types, deployment modes, operation scales, end-user types, and key geographical regions.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the cell and gene therapy supply chain software market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

Azenta Life Sciences

Biocair

BioLife Solutions

CareDx

Cryoport

Lonza

NMDP BioTherapies

TraceLink

TrakCel

Veeva Systems

Emerson

LabVantage Solutions

Marken

MasterControl

QuickSTAT

Siemens

Stafa Cellular Therapy

Steiner

STEMSOFT Software

TECHNIDATA

Thermo Fisher Scientific